Hospital's inpatient service paused for a month
Admissions to Kent Community Health NHS Foundation Trust's Faversham Cottage Hospital were paused on 27 June due to a rising number of nursing vacancies and sickness, particularly in critical leadership roles.
The trust later made the decision to not reopen to admissions and to temporarily stop the inpatient service while a full review of staffing was carried out.
Mairead McCormick, the trust's chief executive, said: "This is not a decision we have taken lightly. Our priority is, and always will be, the safety and wellbeing of our patients, staff and volunteers."
All other services at the hospital, which provides rehabilitation for patients, are unaffected.
Ms McCormick said: "During the past couple of months we have been working hard to bolster staffing; transferring colleagues from alternative hospitals, recruiting to vacant posts, supporting staff to return to work and using our bank and agency workforce.
"Despite these efforts, it is no longer sustainable to continue to use a temporary workforce and re-deploy staff from our other hospitals, placing other services at risk."
The trust says it will work with staff and partners to minimise disruption and offer alternative temporary roles to allow more people to receive care in their own homes or at other community hospitals.
Faversham and Mid Kent's Conservative MP Helen Whately says she is "deeply concerned" about the future of the hospital.
She added: "Of course the hospital needs to be safely staffed, but there should have been warnings to the community before now if it was at risk.
"The Cottage Hospital is an integral part of Faversham and it must reopen."
The trust, which has been contacted for more information, has committed to reviewing its decision within a month.
Follow BBC Kent on Facebook, on X, and on Instagram. Send your story ideas to southeasttoday@bbc.co.uk or WhatsApp us on 08081 002250.
New plan will fundamentally rewire NHS, says PM
NHS AI pilot aims to ease administrative burden
Hospitals in South East given £67m for repairs
Kent Community Health NHS Foundation Trust
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Patients would rather see a GP than pharmacists and nurses, study finds
Patients would much rather see a GP than a pharmacist or nurse, new research suggests. A study found that people often like to see a GP and still prefer in-person appointments, considering them the 'gold standard'. The review of 33 existing studies, from the University of Southampton, also found patients often like to choose a specific doctor to maintain continuity of care. Trust and confidence decreased when patients wanted to see a GP but were directed to a nurse or other health worker instead, it added. The study noted people also wanted easier ways to book GP appointments, clearer phone options, shorter recorded messages, and simple online routes with quick responses. It comes after the Government published its 10-year health plan which intends to massively increase use of the NHS App, as well as recruit more GPs. An improved app will give patients more control over booking, moving and cancelling appointments, as well as quicker access to medics and other forms of care. The new study, published in the British Journal of General Practice, suggested confidence and trust scores appeared to be lower when people wanted a face-to-face appointment and received a call instead. The public also wanted clear details on the roles of different NHS workers, it found. Lead author Helen Atherton, professor of primary care research, said: 'Patients want a deeper connection with their doctor's practice, better communication, and the choice to see the right professional in the best way for them. 'The NHS needs to better understand what people want so it can shape its services to work for patients. 'Ignoring these fundamental needs will only exacerbate the issues it currently faces.' Writing in the journal, Prof Atherton and colleagues added: 'Patients wanted a nearby practice, with clean waiting rooms, easy appointment booking using simple systems and with short waiting times, and to be kept informed about the process.' In particular, researchers found that, for medication reviews and long-term conditions, patients preferred seeing someone they were familiar with. The research also suggested that, where a patient's condition was worsening, 69.5% of patients reported preferring to consult a GP than a pharmacist and 42.7% strongly agreed or agreed that they would prefer to consult with a GP rather than a pharmacist. Professor Kamila Hawthorne, chair of the Royal College of GPs, said: 'It's really encouraging to see how much patients value the care, and continuity of care, their GP provides – there are some things that only a GP can do for their patients, but it's also important that patients don't feel somehow short-changed if they're offered an appointment with another member of our highly-skilled multi-disciplinary team. 'Not all patients need to see a GP. Procedures such as blood tests, routine management of non-complex long-term conditions, the monitoring of repeat prescriptions, or assessment of a painful joint, for example, can be carried out by some of the various other members of the team who now work in general practice, such as nursing staff, mental health professionals, clinical pharmacists and physiotherapists. 'This also alleviates workload on GPs, allowing us to spend time with those patients with complex health needs who really do need our expert medical attention. 'However, we know that even when working as part of multi-disciplinary teams, patients often struggle to access their GP when they need to – and we share their frustrations. 'This is due to decades of under-funding of general practice and poor workforce planning, which has meant patient need for our care has escalated in recent years, while GP numbers have sadly not risen in step. 'We need thousands more GPs, and the recently published 10-Year health plan commits to providing these. 'We're now looking ahead to the revised long-term workforce plan, due later this year, to see how the Government plans to recruit more GPs and keep more GPs in the profession for longer – but also address some of the nonsensical issues GPs are reporting that they can't find appropriate employment upon qualification.' Henry Gregg, chief executive of the National Pharmacy Association, said: 'It's not surprising that people want to see a GP when they go to a GP surgery but all our research and experience shows that people are very happy to visit a pharmacy if they can access treatment or advice quickly without having to wait to see a GP. 'Pharmacists are highly trained medical professionals who offer first-class care for a range of ailments quickly and conveniently and will send patients to a GP or hospital if needs be. 'Increasingly people will be able to pop into a community pharmacy and see a highly qualitied pharmacist for things like screening, check-ups, HRT, weight management or ongoing care without lengthy waits, freeing their NHS colleagues in hospitals and GPs to do more and offering patients the choice and convenience we all want to see.' Royal College of Nursing chief nursing officer, Lynn Woolsey, said: 'Nursing staff are an integral part of any general practice delivering a range of services to patients. 'They lead public health clinics, run screening and vaccination programmes, support patients in the management of chronic disease and can diagnose and prescribe.'
Yahoo
3 hours ago
- Yahoo
FDA Grants Priority Review for Merck & Co's (MRK) WINREVAIR
Merck & Co., Inc. (NYSE:MRK) is one of the . On July 2, Merck & Co., Inc. (NYSE:MRK) announced that the FDA has accepted and granted priority review to its supplemental Biologics License Application for WINREVAIR. Merck & Co., Inc.'s (NYSE:MRK) WINREVAIR was previously approved in 2024 for treating adults with pulmonary arterial hypertension. The treatment aims to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events. The current application seeks to update the US product label based on the results of the Phase 3 ZENITH trial. A close-up of a person's hand holding a bottle of pharmaceuticals. The ZENITH trial is notable for being the first Phase 3 PAH study to use a primary endpoint focused solely on major morbidity and mortality events. The results demonstrated a 76% reduction in the risk of a composite outcome of all-cause death, lung transplantation, and hospitalization for PAH lasting 24 hours or more, compared to placebo. The FDA has set a target action date of October 25, 2025, under the Prescription Drug User Fee Act. Merck & Co., Inc. (NYSE:MRK) is a leading healthcare company that operates through two main segments including the Pharmaceutical and Animal Health Segments. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
The dangerous anti-abortion victory buried in Trump's megabill
The Atlantic called the president's 'One Big Beautiful Bill Act' the biggest anti-abortion victory since Roe v. Wade was overturned. That's because the mega-bill includes a provision that will bar Planned Parenthood from receiving Medicaid reimbursements – not just for abortion but for any health service they provide. Michele Goodwin, Professor of Constitutional Law & Global Health Policy at Georgetown Law is among the many experts warning that this defunding will have a devastating impact on reproductive healthcare, saying in many of the communities served by Planned Parenthood, 'there's no other place for [patients] to go. There's no other clinic, there's no other county provider, and we are talking about basic health care, like getting vaccinated or even getting prenatal care and postnatal care.' Amanda Zurawski, a reproductive rights activist who nearly died after being denied an abortion under Texas' ban, says stories like hers used to be shocking but are becoming so commonplace, as access to reproductive care is rolled back, that no one notices them anymore. 'We're seeing [lawmakers] coordinate these orchestrated efforts to restrict access, you know, in more sinister and unfortunately creative ways, and it's working. And I think we have to really stay vigilant, and we have to keep an eye on our elected officials,' Zurawski says.
